Use of remifentanil in an infant with surgically repaired Shone's syndrome

Tsiotou, Adelais G.; Matsota, Paraskevi; Kouptsova, Elena; Papageorgiou-Brousta, Mary

doi:10.1046/j.1460-9592.2003.01135.x

Pediatric Anesthesia

2004

DOI: 10.1046/j.1460-9592.2003.01135.x

|View full text |Cite

Use of remifentanil in an infant with surgically repaired Shone's syndrome

Adelais G. Tsiotou

Paraskevi Matsota

Elena Kouptsova

et al.

Abstract: We describe the use of remifentanil in an infant with a partially repaired Shone's syndrome who required tendon lengthening because of congenital clubfoot. Remifentanil has unique properties, making it a potentially useful and predictable agent for infants with significant comorbidity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Experience with Remifentanil in Neonates and Infants

Welzing

Roth

2006

Drugs

View full text Add to dashboard Cite

Remifentanil is a relatively new synthetic opioid, which is not licensed worldwide for neonates and infants. Because of its unique pharmacokinetic properties with a short recovery profile, it could be the ideal opioid for neonates and infants, who are especially sensitive to respiratory depression by opioids. Therefore, we conducted a MEDLINE search on all articles dealing with the use of remifentanil in this important subgroup of patients. Most experience with remifentanil in neonates and infants is as maintenance anaesthesia during surgery. In approximately 300 neonates and infants, remifentanil proved to be an effective and safely used opioid for this indication. However, very limited data exist on remifentanil for analgesia and sedation of mechanically ventilated paediatric intensive care patients. Further research with remifentanil in neonates and infants should focus on this group of patients because remifentanil, with its very short context-sensitive half-life, could result in shorter extubation times compared with commonly used opioids such as morphine or fentanyl.

show abstract

Experience with Remifentanil in Neonates and Infants

Welzing

Roth

2006

Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Use of remifentanil in an infant with surgically repaired Shone's syndrome

Abstract: We describe the use of remifentanil in an infant with a partially repaired Shone's syndrome who required tendon lengthening because of congenital clubfoot. Remifentanil has unique properties, making it a potentially useful and predictable agent for infants with significant comorbidity.

Cited by 1 publication

References 11 publications

Experience with Remifentanil in Neonates and Infants

Experience with Remifentanil in Neonates and Infants

Contact Info

Product

Resources

About